Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 9/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | APP | P05067 | 2/20 | 0.60 |
| ▸ | PDE5A | O76074 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29648985 | 0.81 | APP (0.60) | CYP1A2CYP2D6CYP3A4HSD17B10TDP1 | |
| SCHEMBL8821164 | 0.81 | APP (0.60) | CYP1A2CYP2D6CYP3A4HSD17B10TDP1 | |
| SCHEMBL3946412 | 0.80 | CCNE2 (0.67) | APPPDE5AKDM4ELMNAMAPT | |
| SCHEMBL29161537 | 0.80 | APP (0.69) | CYP1A2APPPDE5ACYP1A1MAPT | |
| SCHEMBL30960995 | 0.79 | NPY5R (0.66) | MAPK1APPPDE5AKDM4ECLK4 | |
| SCHEMBL2257238 | 0.79 | NPY5R (0.66) | MAPK1APPPDE5AKDM4ECLK4 | |
| SCHEMBL14606852 | 0.78 | BCHE (0.68) | CYP1A2CYP2D6CYP3A4CYP2C19HSD17B10 | |
| SCHEMBL12736488 | 0.78 | LMNA (0.61) | CYP1A2CYP2D6CYP3A4CYP2C19HSD17B10 | |
| SCHEMBL3598923 | 0.78 | HTR3A (0.57) | HTTALDH1A1HTR3A | |
| SCHEMBL21055788 | 0.78 | HRH4 (0.57) | CYP1A2CYP2D6CYP3A4CYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024083886-A1 | RNA-BINDING MOLECULES WITH A SMALL CORE SCAFFOLD (R-SCORE) AND USES THEREOF | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-04-25 | — | — | WO | disclosed |
| EP-4357343-A1 | RNA-BINDING MOLECULES WITH A SMALL CORE SCAFFOLD (R-SCORE) AND USES THEREOF | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-04-24 | — | — | EP | disclosed |
| US-20240065302-A1 | SWEETENER COMPOSITIONS COMPRISING MOGROSIDES AND USES THEREOF | FIRMENICH INCORPORATED | 2024-02-29 | — | — | US | disclosed |
| EP-3442947-B1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | EPIZYME INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3442947-B1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | EPIZYME INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220008418-A1 | Aminoquinoline Derivatives and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-13 | — | — | US | disclosed |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2021-07-01 | — | — | US | disclosed |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2021-07-01 | — | — | US | disclosed |
| CN-107365319-B | Modulation of chemosensory receptors and ligands associated therewith | 弗门尼舍公司 | 2020-10-27 | — | — | CN | disclosed |
| CN-110115365-A | The adjusting that actinism receptor and relative ligand are carried out | 西诺米克斯公司 | 2019-08-13 | — | — | CN | disclosed |
| US-20080306053-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306053-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| CN-1582281-A | MCH receptor antagonists | TAISHO PHARMACEUTICAL CO LTD (JP) | 2005-02-16 | — | — | CN | disclosed |
| EP-1432693-A2 | MCH RECEPTOR ANTAGONISTS | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003028641-A2 | MCH RECEPTOR ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-04-10 | — | — | WO | disclosed |
| WO-1997020822-A1 | QUINAZOLIN-2,4-DIAZIRINES AS NPY RECEPTOR ANTAGONIST | NOVARTIS AG (CH) | 1997-06-12 | — | — | WO | disclosed |
| WO-1997020823-A2 | 2-AMINO QUINAZOLINE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 1997-06-12 | — | — | WO | disclosed |
| EP-0227450-A2 | Substituted 5,6-Dialkoxyquinazoline Derivatives | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-07-01 | — | — | EP | disclosed |
| US-4672116-A | CARDIOTONIC AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008418-A1 | Aminoquinoline Derivatives and Uses Thereof | LRRK2, NLN, AADAT | CYP1A2 2110/4885CYP2D6 1830/4885CYP3A4 2415/4885 |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | CYP1A2 615/4885CYP2D6 671/4885CYP3A4 1720/4885 |
| US-20080306053-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | OR51E2, TAS2R50, TAS2R30 | CYP1A2 4860/4885CYP2D6 4747/4885CYP3A4 4548/4885 |
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | MCHR1, MCHR2, MC4R | CYP1A2 686/4885CYP2D6 763/4885CYP3A4 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.